Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42499 ↗Kurz gefasst
Leserbrief in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Tomoyuki Kawada. Beteiligte Einrichtung: Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Gout, Hyperuricemia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
ORCID-Profile: Tomoyuki Kawada
Zitieren
APA
Kawada, T. (2023). Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al. Arthritis & Rheumatology. https://doi.org/10.1002/art.42499
Vancouver
Kawada T. Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al. Arthritis & Rheumatology. 2023. doi:10.1002/art.42499
BibTeX
@article{Kawada2023,
author = {Kawada, Tomoyuki},
title = {Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42499}
}
EUVIMED